Hypothesis: Uric acid, nephron number, and the pathogenesis of essential hypertension

Kidney International

Volumn 66, Issue 1, 2004, Pages 281-287

  Feig, Daniel I ^a   Nakagawa, Takahiko ^b   Karumanchi, S Ananth ^b   Oliver, William J ^b   Kang, Duk Hee ^b   Finch, Jennifer ^b   Johnson, Richard J ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

Children; Clinical trial; Endothelium; Essential hypertension

Indexed keywords

ALLOPURINOL; URIC ACID;

AMBULATORY CARE; ANAMNESIS; ARTICLE; BIRTH WEIGHT; BLOOD PRESSURE; CELL FUNCTION; CHILD; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); ENDOTHELIUM CELL; EVALUATION; FAMILY HISTORY; GLOMERULUS; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPOTHESIS; MEDICAL RECORD; NEPHRON; NONHUMAN; ONSET AGE; OPEN STUDY; PARENT; PATHOGENESIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCREENING; SERUM; TISSUE CULTURE;

EID: 3042769305     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.00729.x     Document Type: Article

References (71)

1. DAHL LK, HEINE M: Primary role of renal homografts in setting chronic blood pressure levels in rats. Circ Res 36:692-696, 1975
2. CURTIS JJ, LUKE RG, DUSTAN HP, et al: Remission of essential hypertension after renal transplantation. N Engl J Med 309:1009-1015, 1983
3. GUYTON AC, COLEMAN TG, COWLEY AV, JR., et al: Arterial pressure regulation. Overriding dominance of the kidneys in long-term regulation and in hypertension. Am J Med 52:584-594, 1972
4. LIFTON RP: Molecular genetics of human blood pressure variation. Science 272:676-680, 1996
5. CAULFIELD M, MUNROE P, PEMBROKE J, et al: Genome-wide mapping of human loci for essential hypertension. Lancet 361:2118-2123, 2003
6. PROVINCE MA, KARDIA SL, RANADE K, et al: A meta-analysis of genome-wide linkage scans for hypertension: The National Heart, Lung and Blood Institute Family Blood Pressure Program. Am J Hypertens 16:144-147, 2003
7. BRENNER BM, GARCIA DL, ANDERSON S: Glomeruli and blood pressure. Less of one, more the other? Am J Hypertens 1:335-347, 1988
8. BARKER DJ: The fetal origins of adult hypertension. J Hypertens Suppl 10:S39-44, 1992
9. BARKER DJ, OSMOND C, GOLDING J, et al: Growth in utero, blood pressure in childhood and adult life, and mortality from cardiovascular disease. BMJ 298:564-567, 1989
10. KONJE JC, BELL SC, MORTON JJ, et al: Human fetal kidney morphometry during gestation and the relationship between weight, kidney morphometry and plasma active renin concentration at birth. Clin Sci (Lond) 91:169-175, 1996
11. HINCHLIFFE SA, LYNCH MR, SARGENT PH, et al: The effect of intrauterine growth retardation on the development of renal nephrons. BJOG 99:296-301, 1992
12. HUGHSON M, FARRIS AB, DOUGLAS-DENTON R, et al: Glomerular number and size in autopsy kidneys: The relationship to birth weight. Kidney Int 63:2113-2122, 2003
13. KELLER J, ZIMMER G, MALL G, et al: Nephron number in patients with primary hypertension. N Engl J Med 348:101-118, 2003
14. BRENNER BM, MEYER TW, HOSTETTER TH: Dietary protein intake and the progressive nature of kidney disease: The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 307:652-659, 1982
15. KIMURA G, BRENNER BM: A method for distinguishing salt-sensitive from non-salt-sensitive forms of human and experimental hypertension. Curr Opin Nephrol Hypertens 2:341-349, 1993
16. GOLDFARB DA, MATIN SF, BRAUN WE, et al: Renal outcome 25 years after donor nephrectomy. J Urol 166:2043-2047, 2001
17. MORITZ A, OLDT M: Ateriolar sclerosis in hypertensive and nonhypertensive individuals. Am J Pathol 13:679-728, 1937
18. SOMMERS S, RELMAN R, SMITHWICK R: Histologic studies of kidney biopsy specimens from patients with hypertension. Am J Pathol 34, 1958
19. TRACY RE: Renovasculopathies of hypertension and the rise of blood pressure with age in blacks and whites. Semin Nephrol 16:126-133, 1996
20. GOLDBLATT H, LYNCH J, HANZAL R, SUMMERVILLE W: Studies on experimental hypertension: I. The production of persistent elevation of systolic blood pressure by means of renal ischemia. J Exp Med 59:347-379, 1934
21. JOHNSON RJ, HERRERA-ACOSTA J, SCHREINER GF, RODRIGUEZ-ITURBE B: Subtle acquired renal injury as a mechanism of salt-sensitive hypertension. N Engl J Med 346:913-923, 2002
22. SELBY JV, FRIEDMAN GD, QUESENBERRY CP, JR.: Precursors of essential hypertension: Pulmonary function, heart rate, uric acid, serum cholesterol, and other serum chemistries. Am J Epidemiol 131:1017-1027, 1990
23. JOSSA F, FARINARO E, PANICO S, et al: Serum uric acid and hypertension: The Olivetti heart study. J Hum Hypertens 8:677-681, 1994
24. MASUO K, KAWAGUCHI H, MIKAMI H, et al: Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 42:474-480, 2003
25. KLEIN R, KLEIN BE, CORNONI JC, et al: Serum uric acid. Its relationship to coronary heart disease risk factors and cardiovascular disease, Evans County, Georgia. Arch Intern Med 132:401-410, 1973
26. FEIG DI, JOHNSON RJ: Hyperuricemia in childhood primary hypertension. Hypertension 42:247-252, 2003
27. BRAND FN, MCGEE DL, KANNEL WB, et al: Hyperuricemia as a risk factor of coronary heart disease: The Framingham Study. Am J Epidemiol 121:11-18, 1985
28. KANNEL WB: Metabolic risk factors for coronary heart disease in women: Perspective from the Framingham Study. Am Heart J 114:413-419, 1937
29. MAZZALI M, HUGHES J, KIM YG, et al: Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 38:1101-1106, 2001
30. MAZZALI M, KANELLIS J, HAN L, et al: Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 282:F991-997, 2002
31. SANCHEZ-LOZADA LG. TAPIA E, AVILA-CASADO C, et al: Mild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol Renal Physiol 283:F1105-1110, 2002
32. NAKAGAWA T, MAZZALI M, KANG DH, et al: Hyperuricemia causes glomerular hypertrophy in the rat. Am J Nephrol 23:2-7, 2003
33. WATANABE S, KANG DH, FENG L, et al: Uric acid hominoid evolution and the pathogenesis of salt-sensitivity. Hypertension 40:355-360, 2002
34. KANELLIS J, WATANABE S, LI JH, et al: Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 41:1287-1293, 2003
35. KANG DH, NAKAGAWA T, FENG L, JOHNSON RJ: Nitric oxide modulates vascular disease in the remnant kidney model. Am J Pathol 161:239-248, 2002
36. FINCH J, MU W, PARRA G, et al: Hyperuricemia induces endothelial dysfunction in rats. Proceedings of the 36th Annual Meeting of the American Society of Nephrology, San Diego, CA, 2003
37. MAZZALI M, KIM YG, SUGA S, et al: Hyperuricemia exacerbates chronic cyclosporine nephropathy. Transplantation 71:900-905, 2001
38. RAO GN, CORSON MA, BERK BC: Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J Biol Chem 266:8604-8608, 1991
39. KANELLIS J, NAKAGAWA T, HERRERA-ACOSTA J, et al: A single pathway for the development of essential hypertension. Cardiol Rev 11:180-196, 2003
40. JOHNSON RJ, GORDON KL, SUGA S, et al: Renal injury and salt-sensitive hypertension after exposure to catecholamines. Hypertension 34:151-159, 1999
41. FRANCO M, TAPIA E, SANTAMARIA J, et al: Renal cortical vasoconstriction contributes to development of salt-sensitive hypertension after angiotensin II exposure. J Am Soc Nephrol 12:2263-2271, 2001
42. QUIROZ Y, PONS H, GORDON KL, JR., et al: Immune cells play a role in the pathogenesis of salt-sensitive hypertension resulting from short-term nitric-oxide synthase inhibition in the rat. Am J Physiol Renal Physiol 281:38-47, 2001
43. ANDOH TF, JOHNSON RJ, LAM T, BENNETT WM: Subclinical renal injury induced by transient cyclosporine exposure is associated with salt-sensitive hypertension. Am J Transplant 1:222-227, 2001
44. KANG DH, KIM YG, ANDOH TF, et al: Post-cyclosporine-mediated hypertension and nephropathy: Amelioration by vascular endothelial growth factor. Am J Physiol Renal Physiol 280:F727-736, 2001
45. HERRERA-ACOSTA J, JOHNSON RJ: Unpublished observations, 2003
46. MURAKAMI K, KOJIMA S, KIMURA G, et al: The association between salt sensitivity of blood pressure and family history of hypertension. Clin Exp Pharmacol Physiol 20(Suppl):61-63, 1992
47. FRIEDMAN GD, SELBY JV, QUESENBERRY CP, JR., et al: Precursors of essential hypertension: Body weight, alcohol and salt use, and parental history of hypertension. Prev Med 17:387-402, 1988
48. FUENTES RM, NOTKOLA IL, SHEMEIKKA S, et al: Familial aggregation of blood pressure: A population-based family study in eastern Finland. J Hum Hypertens 14:441-445, 2000
49. BURKE V, GRACEY MP, BEILIN LJ, MILLIGAN RA: Family history as a predictor of blood pressure in a longitudinal study of Australian children. J Hypertens 16:269-276, 1998
50. KITAMOTO Y, TOKUNAGA H, TOMITA K: Vascular endothelial growth factor is an essential molecule for mouse kidney development: Glomerulogenesis and nephrogenesis. J Clin Invest 99:2351-2357, 1997
51. KANG DH, JOHNSON RJ: Uric acid induces C-reactive protein expression via upregulation of angiotensin type I receptor in vascular endothelial and smooth muscle cells. J Am Soc Nephrol 14:F-PO336, 2003
52. WARING W, WEBB D, MAXWELL S: Effect of local hyperuricemia on endothelial function in the human forearm vascular bed. Br J Clin Pharmacol 48:511, 2000
53. KANABROCKI EL, THIRD JL, RYAN MD, et al: Circadian relationship of serum uric acid and nitric oxide. JAMA 283:2240-2241, 2000
54. MAXWELL AJ, BRUINSMA KA: Uric acid is closely linked to vascular nitric oxide activity. Evidence for mechanism of association with cardiovascular disease. J Am Coll Cardiol 38:1850-1858, 2001
55. DOEHNER W, SCHOENE N, RAUCHHAUS M, et al: Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: Results from 2 placebo-controlled studies. Circulation 105:2619-2624, 2002
56. BUTLER R, MORRIS AD, BELCH JJ, et al: Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension 35:746-751, 2000
57. CHANG FM, CHOW SN, HUANG HC, et al: The placental transfer and concentration difference in maternal and neonatal serum uric acid at parturition: Comparison of normal pregnancies and gestosis. Biol Res Pregnancy Perinatal 8:35-39, 1987
58. SHAMMAS AG, MAAYAH JF: Hypertension and its relation to renal function 10 years after pregnancy complicated by pre-eclampsia and pregnancy induced hypertension. Saudi Med J 21:190-192, 2000
59. ABER GM: Intrarenal vascular lesions associated with preeclampsia. Nephron 21:297-309, 1978
60. SAGEN N, HARAM K, NILSEN ST: Serum urate as a predictor of fetal outcome in severe pre-eclampsia. Acta Obstet Gynecol Scand 63:71-75, 1984
61. REDMAN CW, BEILIN LJ, BONNAR J, WILKINSON RH: Plasma-urate measurements in predicting fetal death in hypertensive pregnancy. Lancet 1:1370-1373, 1976
62. POWERS R, WOO K, PATRICK T, et al: Gestational hypertension and hyperuricemia even without proteinuria identifies women with increased cellular fibronectin. J Soc Gynecol Investig 10:A247, 2003
63. WOO K, POWERS R, PATRICK T, et al: Gestational hypertension and hypertension without proteinuria is an indicator of poor fetal outcome. J Soc Gynecol Investig 10:A241, 2003
64. MAYNARD SE, MIN JY, MERCHAN J, et al: Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111:649-658, 2003
65. SAVVIDOU MD, HINGORANI AD, TSIKAS D, et al: Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia. Lancet 361:1511-1517, 2003
66. TADDEI S, SALVETTI A: Endothelial dysfunction in essential hypertension: Clinical implications. J Hypertens 20:1671-1674, 2002
67. BELGORE FM, LIP GY, BAREFORD D, et al: Plasma levels of vascular endothelial growth factor (VEGF) and its receptor, Flt-1, in haematological cancers: A comparison with breast cancer. Am J Hematol 66:59-61, 2001
68. SURDACKI A, NOWICKI M, SANDMANN J, et al: Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 33:652-658, 1999
69. SHIRLEY DG, WALTER SJ: Acute and chronic changes in renal function following unilateral nephrectomy. Kidney Int 40:62-68, 1991
70. NOON JP, WALKER BR, WEBB DJ, et al: Impaired microvascular dilatation and capillary rarefaction in young adults with a predisposition to high blood pressure. J Clin Invest 99:1873-1879, 1997
71. KANG DH, NAKAGAWA T, FENG L, et al: A role for uric acid in the progression of renal disease. J Am Soc Nephrol 13:2888-2897, 2002